Apellis Pharmaceuticals Inc (NAS:APLS)
$ 39.68 -3.92 (-8.99%) Market Cap: 4.82 Bil Enterprise Value: 5.07 Bil PE Ratio: 0 PB Ratio: 18.04 GF Score: 38/100

Apellis Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript

Jun 09, 2022 / 08:30PM GMT
Release Date Price: $41.69 (-4.93%)
Christopher Lawrence Howerton
Jefferies LLC, Research Division - Equity Analyst

Okay. Good afternoon, everybody. Thank you so much for joining us. My name is Chris Howerton, part of the biotechnology research team here at Jefferies. Really excited to be hosting a fireside chat with one of the most exciting companies I cover, Apellis. So on behalf of the management team, we have both the CFO, Tim Sullivan; and Adam Townsend, the Chief Commercial Officer. So thanks for joining us.

Timothy E. Sullivan
Apellis Pharmaceuticals, Inc. - CFO & Treasurer

Thank you for having us.

Adam J. Townsend
Apellis Pharmaceuticals, Inc. - Chief Commercial Officer

Thank you.

Questions & Answers

Christopher Lawrence Howerton
Jefferies LLC, Research Division - Equity Analyst

All right. So I think for me, the biggest opportunity might be for pegcetacoplan in geographic atrophy. So where are we at in terms of the clinical package? And what will be submitted to the FDA at this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot